^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HH2710

    i
    Other names: HH2710, HH 2710, HH-2710
    Associations

    News

    Trials
    Company:
    HaiHe Biopharma
    Drug class:
    ERK2 inhibitor, ERK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (clinicaltrials.gov)
    P1/2, N=37, Terminated, Haihe Biopharma Co., Ltd. | N=150 --> 37 | Trial completion date: Dec 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Mar 2023; Sponsor business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation • BRAF V600 • ER mutation • NRAS Q61 • NRAS G13 • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF L597
    |
    HH2710